Position in ENTA
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$845,539
+$329,547 QoQ
Shares Held
66,947
+104.6% QoQ
Ownership
0.230%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2021
9 quarters on record
Voting authority
Sole 99%
Shared 0%
None 1%
Common Shares in ENTA Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026FRANKLIN RESOURCES INC holds $7,058,625,627 across 166 Biotechnology names. ENTA ranks #123 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,722,071 | $2,103,180,930 | |
| 2 | ASND |
Ascendis Pharma A/S
|
2,051,948 | $469,342,063 | |
| 3 | INSM |
INSMED Inc
|
2,617,251 | $427,972,880 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
1,958,940 | $370,337,604 | |
| 5 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
551,132 | $246,102,477 | |
| 6 | BBIO |
BridgeBio Pharma, Inc.
|
2,438,925 | $181,114,568 | |
| 7 | ARGX |
Argenx SE
|
233,493 | $170,508,261 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
470,390 | $155,637,935 |
All Filings in ENTA
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $845,539 | 66,947 | Shares | Defined | 2026-05-13 | |
| 2025-12-31 | $515,992 | 32,720 | Shares | Defined | 2026-02-11 | |
| 2024-09-30 | $265,142 | 25,593 | Shares | Defined | 2024-11-27 | |
| 2024-06-30 | $339,540 | 26,179 | Shares | Defined | 2024-08-14 | |
| 2024-03-31 | $507,491 | 29,066 | Shares | Defined | 2024-05-13 | |
| 2023-03-31 | $201,955 | 4,994 | Shares | Defined | 2023-05-12 | |
| 2022-12-31 | $233,761 | 5,025 | Shares | Defined | 2023-02-10 | |
| 2022-09-30 | $310,025 | 5,977 | Shares | Defined | 2022-11-14 | |
| 2021-12-31 | $206,466 | 2,761 | Shares | Defined | 2022-02-11 | |
| No filing history on record for this holder in this stock. | ||||||